URBANA, Ill. — Medications such as Ozempic, Wegovy, and Mounjaro are reshaping the landscape of weight management, according to a University of Illinois expert. Originally developed to treat type 2 diabetes, these GLP-1 drugs are now gaining popularity as a potent tool for weight loss.
Patrick Sweeney, an assistant professor of molecular and integrated physiology at the University of Illinois, highlights the remarkable progress in weight loss treatments. While weight loss medications have existed for years, the current generation of GLP-1 drugs allows patients to shed significantly more weight compared to older treatments, some of which were available just a decade ago.
“These medications are truly transforming the fields of obesity and diabetes management,” Sweeney stated, emphasizing the groundbreaking impact of these drugs.
Looking ahead, Sweeney believes the future of these drugs is poised to make them among the most widely prescribed treatments, both in the United States and potentially worldwide.
A 2024 survey revealed that over 12% of U.S. adults have used GLP-1 medications like Ozempic, with 40% of users taking the drugs specifically for weight loss. This marks a sharp increase from 2023, when only 4% of American adults had reported using these medications.
“These medications make it possible to lose a significant amount of weight—much more than traditional dieting and exercise can achieve alone,” Sweeney explained.
However, as the popularity of these drugs grows, Sweeney urges caution. He recommends that individuals who are of healthy weight or only slightly overweight consider alternative methods before turning to medication, as the drugs are still relatively new. He also raised concerns over the widespread use among celebrities, suggesting that while effective, medication may not always be the safest or most sustainable solution for the broader population.
Despite these warnings, the growing demand for weight loss drugs is expected to have a lasting influence on the pharmaceutical industry.
“The success of these treatments will likely inspire pharmaceutical companies to develop similar drugs, which could ultimately reduce costs and make these medications more accessible to a larger population,” Sweeney predicted.
Currently, however, the cost of these medications remains a significant barrier for many. Sweeney noted that millions of individuals stand to benefit from the drugs, but their high cost keeps them out of reach for many potential users.
While the drugs are showing impressive results, Sweeney cautioned that the long-term effects are still not fully understood. A known drawback is that when patients stop taking the medications, weight gain is often rapid. This could result in the need for lifelong treatment to maintain weight loss.
“These medications may be effective in the short term, but without ongoing use, many patients may find it challenging to keep the weight off,” he explained.
Looking beyond obesity and diabetes, Sweeney is optimistic about the potential for these drugs to address other health issues, such as cardiovascular diseases, inflammation, and even addiction.
With their growing popularity and potential for wider applications, GLP-1 medications are set to play a central role in the future of weight management and overall health care.
Related Topics:
How Much Weight Can You Lose In A Month With Ozempic
